↓ Skip to main content

Recombinant amyloid beta-peptide production by coexpression with an affibody ligand

Overview of attention for article published in BMC Biotechnology, October 2008
Altmetric Badge

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
92 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Recombinant amyloid beta-peptide production by coexpression with an affibody ligand
Published in
BMC Biotechnology, October 2008
DOI 10.1186/1472-6750-8-82
Pubmed ID
Authors

Bertil Macao, Wolfgang Hoyer, Anders Sandberg, Ann-Christin Brorsson, Christopher M Dobson, Torleif Härd

Abstract

Oligomeric and fibrillar aggregates of the amyloid beta-peptide (Abeta) have been implicated in the pathogenesis of Alzheimer's disease (AD). The characterization of Abeta assemblies is essential for the elucidation of the mechanisms of Abeta neurotoxicity, but requires large quantities of pure peptide. Here we describe a novel approach to the recombinant production of Abeta. The method is based on the coexpression of the affibody protein ZAbeta3, a selected affinity ligand derived from the Z domain three-helix bundle scaffold. ZAbeta3 binds to the amyloidogenic central and C-terminal part of Abeta with nanomolar affinity and consequently inhibits aggregation. Coexpression of ZAbeta3 affords the overexpression of both major Abeta isoforms, Abeta(1-40) and Abeta(1-42), yielding 4 or 3 mg, respectively, of pure 15N-labeled peptide per liter of culture. The method does not rely on a protein-fusion or -tag and thus does not require a cleavage reaction. The purified peptides were characterized by NMR, circular dichroism, SDS-PAGE and size exclusion chromatography, and their aggregation propensities were assessed by thioflavin T fluorescence and electron microscopy. The data coincide with those reported previously for monomeric, largely unstructured Abeta. ZAbeta3 coexpression moreover permits the recombinant production of Abeta(1-42) carrying the Arctic (E22G) mutation, which causes early onset familial AD. Abeta(1-42)E22G is obtained in predominantly monomeric form and suitable, e.g., for NMR studies. The coexpression of an engineered aggregation-inhibiting binding protein offers a novel route to the recombinant production of amyloidogenic Abeta peptides that can be advantageously employed to study the molecular basis of AD. The presented expression system is the first for which expression and purification of the aggregation-prone Arctic variant (E22G) of Abeta(1-42) is reported.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 1%
Sweden 1 1%
United Kingdom 1 1%
Sri Lanka 1 1%
Argentina 1 1%
Romania 1 1%
Spain 1 1%
United States 1 1%
Unknown 84 91%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 23 25%
Researcher 18 20%
Professor > Associate Professor 7 8%
Student > Master 7 8%
Student > Bachelor 6 7%
Other 19 21%
Unknown 12 13%
Readers by discipline Count As %
Agricultural and Biological Sciences 32 35%
Chemistry 15 16%
Biochemistry, Genetics and Molecular Biology 14 15%
Medicine and Dentistry 4 4%
Chemical Engineering 3 3%
Other 9 10%
Unknown 15 16%